Measurement and Data Analysis Services Using Liquid Biopsy
Liquid biopsy is a minimally invasive technique that uses biological fluids such as blood for the purpose of diagnosis and the selection of therapeutic agent. In recent years, liquid biopsy has gained significant attention as an alternative to conventional endoscopic and needle biopsies, which place a significant burden on patients. In addition, liquid biopsy enables repeated blood sampling and disease monitoring for a long period of time.
We offer comprehensive analytical services for the principal analytes used in liquid biopsy, including exosomes (extracellular vesicles, EVs), circulating tumor cells (CTCs), and cell-free DNA (cfDNA). We provide extensive support for your research and development related to liquid biopsy technologies.
Major Service Menu*
| Exosomes (Extracellular Vesicles: EVs) | We provide end-to-end analytical services, ranging from their enrichment, to purification and quality evaluation of exosomes. Our platform enables the quantification of key biomarkers, including microRNAs and proteins contained in exosomes. |
|---|---|
| Circulating Tumor Cells (CTCs) | Utilizing a microfluidic chip cell sorter, we isolate CTCs from up to 8 mL of peripheral blood. We perform comprehensive biomarker profiling, including surface marker and target molecule expression analyses, as well as mutation detection in relevant genes. |
| Cell-free DNA (cfDNA or circulating Tumor DNA, ctDNA) | We extract cfDNA from blood or plasma samples and employ PCR and next-generation sequencing (NGS) to detect and characterize genetic mutations. cfDNA consists of DNA fragments approximately 170 base pairs in length, released into the bloodstream. In oncology, cfDNA is being actively studied and utilized as a biomarker for identifying cancer driver mutations, monitoring disease progression and recurrence, and predicting therapeutic response. Therefore, highly sensitive analytical methods are required to distinguish tumor-derived cfDNA from normal cell-derived cfDNA. We provide cfDNA extraction service from blood or plasma and mutation analysis using quantitative PCR and NGS with molecular barcoding in order to achieve highly sensitive detection of genetic alterations. |
- Exosome Research Services: Biomarkers for Drug Development
- High-Purity Isolation and Biomarker Analysis of Circulating Tumor Cells (CTCs)
- *Please note:All services are provided strictly for research purposes and are not intended for diagnostic use.
Points to Consider for Human Clinical Samples
- Ethical Compliance: Approval by the Institutional Review Board (IRB) or an equivalent ethics committee at the client’s institution is required to ensure scientific and ethical appropriateness.
- Informed Consent and Privacy: All samples must be de-identified, with informed consent obtained, to protect patient privacy.
- Biosafety: Samples containing agents classified as biosafety level 3 (BSL-3) or higher, or those positive for human immunodeficiency virus (HIV), are generally not accepted.
Contact Us for Services
